Oppenheimer analyst Leland Gershell upgraded Argenx to Outperform from Perform with a $546 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx (ARGX) Q2 Earnings Cheat Sheet
- argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
- Argenx price target raised to $504 from $490 at H.C. Wainwright
- Zai Lab, Argenx announce China NMPA approval for efgartigimod alfa injection
- argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China